Compass Pathways plc, a biotechnology company focused on expanding patient access to evidence-based innovation, announced that it will release new clinical data tomorrow from two ongoing Phase 3 trials evaluating COMP360 for treatment-resistant depression (TRD).
COMP360 is a synthetic, proprietary formulation of psilocybin. The company will present new data from Part A and Part B of COMP005 and Part A of COMP006. The results will be released on February 17 at 6:30 a.m. ET. Compass management will then host a webinar at 8:00 a.m. ET to discuss the findings.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
